396731-14-9
Chemical Structure
rel-Avibactam
Synonym(s): rel-NXL-104 free acid; rel-AVE1330A free acid
- CAS No.: 396731-14-9
- Formula:C7H11N3O6S
- Molecular Weight:265.24
IUPAC Name: (1S,2R,5S)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate
InChIKey: NDCUAPJVLWFHHB-CRCLSJGQSA-N
SMILES: NC([C@@H]1[N@]2C(N([C@](CC1)([H])C2)OS(=O)(O)=O)=O)=O
Biological Activity: rel-Avibactam (rel-NXL-104 free acid) is an isomer of Avibactam (HY-14879). Avibactam is a β-lactamase inhibitor with an IC50 of 8 nM against TEM-1 β-lactamase and an IC50 of 80 nM against P99 β-lactamase. Avibactam exhibits no significant intrinsic antibacterial activity when used alone. Avibactam restores the activity of Ceftazidime (HY-B0593) against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Avibactam does not enhance the activity of Ceftazidime against Acinetobacter spp., Burkholderia spp., or most anaerobic Gram-negative bacilli. Avibactam is used in research related to Gram-negative bacterial infections[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
rel-Avibactam | rel-Avibactam (rel-NXL-104 free acid) is an isomer of Avibactam (HY-14879). Avibactam is a β-lactamase inhibitor with an IC50 of 8 nM against TEM-1 β-lactamase and an IC50 of 80 nM against P99 β-lactamase. Avibactam exhibits no significant intrinsic antibacterial activity when used alone. Avibactam restores the activity of Ceftazidime (HY-B0593) against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Avibactam does not enhance the activity of Ceftazidime against Acinetobacter spp., Burkholderia spp., or most anaerobic Gram-negative bacilli. Avibactam is used in research related to Gram-negative bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lagacé-Wiens P, et al. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core evidence. 2014;9:13-25. [Content Brief]
- [2]. Bonnefoy A, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. The Journal of antimicrobial chemotherapy. 2004 Aug;54(2):410-7.
